Karyopharm Financial Statements From 2010 to 2026

Stocks . USA . 
Stock . Karyopharm Therapeutics
KPTI Stock  USD 10.07  0.04  0.40%   
Karyopharm Therapeutics' financial statements offer valuable quarterly and annual insights to potential investors, highlighting the company's current and historical financial position, overall management performance, and changes in financial standing over time. Key fundamentals influencing Karyopharm Therapeutics' valuation are provided below:
Gross Profit
14.5 M
Profit Margin
(1.34)
Market Capitalization
184.7 M
Enterprise Value Revenue
2.3778
Revenue
146.1 M
We have found one hundred twenty available fundamental ratios for Karyopharm Therapeutics, which can be analyzed and compared to other ratios and to its peers in the industry. Traders should compare all of Karyopharm Therapeutics last-minute fundamentals against the fundamentals between 2010 and 2026 to make sure the company is sustainable this year. The current Market Cap is estimated to decrease to about 90 M. Enterprise Value is estimated to decrease to about 183.3 M

Karyopharm Therapeutics Total Revenue

153.37 Million

Check Karyopharm Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Karyopharm Therapeutics' main balance sheet or income statement drivers, such as Depreciation And Amortization of 586.2 K, Interest Expense of 48.1 M or Selling General Administrative of 71.8 M, as well as many indicators such as Price To Sales Ratio of 0.52, Dividend Yield of 0.0 or Days Sales Outstanding of 53.98. Karyopharm financial statements analysis is a perfect complement when working with Karyopharm Therapeutics Valuation or Volatility modules.
  
Build AI portfolio with Karyopharm Stock
Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.

Karyopharm Therapeutics Balance Sheet

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Total Assets103 M108.4 M188.2 M
Slightly volatile
Total Current Liabilities96.7 M92.1 M40.4 M
Slightly volatile
Property Plant And Equipment Net4 M4.7 M3.4 M
Slightly volatile
Current Deferred Revenue30.3 M28.8 M14 M
Slightly volatile
Accounts Payable3.7 M4 M3.3 M
Slightly volatile
Cash97.1 M60.5 M84 M
Slightly volatile
Non Current Assets Total5 M5.3 M14.5 M
Very volatile
Other Assets1.091.155 M
Pretty Stable
Cash And Short Term Investments60.6 M63.7 M154.3 M
Slightly volatile
Common Stock Shares Outstanding17.8 M10.9 M15.4 M
Pretty Stable
Liabilities And Stockholders Equity103 M108.4 M188.2 M
Slightly volatile
Non Current Liabilities Total158.8 M309.3 M137.7 M
Slightly volatile
Other Current Assets6.9 M9.2 M6 M
Slightly volatile
Other Stockholder Equity857.6 M1.5 B738.3 M
Slightly volatile
Total Liabilities421.4 M401.3 M185.1 M
Slightly volatile
Property Plant And Equipment Gross15.7 M14.9 M5.8 M
Slightly volatile
Total Current Assets98 M103.1 M173.7 M
Slightly volatile
Short Term Debt23.1 M22 M12.1 M
Slightly volatile
Property Plant Equipment2.2 M1.3 M1.8 M
Pretty Stable
Common Stock Total Equity14.5 K13.8 K7.1 K
Slightly volatile
Capital Surpluse824.8 M1.5 B774 M
Slightly volatile
Common Stock8.3 K14 K6.8 K
Slightly volatile
Other Liabilities260.4 M248 M94.8 M
Slightly volatile
Net Invested Capital1.2 M1.2 M119.3 M
Slightly volatile
Net Working Capital54.9 M57.8 M138.6 M
Pretty Stable
Short and Long Term Debt Total183.9 M239.3 M153.3 M
Slightly volatile
Long Term Debt Total121.2 M135.6 M110.6 M
Slightly volatile
Capital Stock10.2 K14.9 K8.1 K
Slightly volatile
Net Receivables27.4 M26.2 M16 M
Slightly volatile
Capital Lease Obligations8.2 M6.4 M12.3 M
Slightly volatile
Non Current Liabilities Other2.1 M2.2 M65.6 M
Slightly volatile
Short and Long Term Debt19.5 M22 M24 M
Slightly volatile

Karyopharm Therapeutics Income Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Depreciation And Amortization586.2 K296 K509.5 K
Slightly volatile
Selling General Administrative71.8 M132.8 M65.9 M
Slightly volatile
Total Revenue153.4 M146.1 M67.1 M
Slightly volatile
Other Operating Expenses191 M236.8 M165.1 M
Slightly volatile
Research Development114 M125.6 M98.7 M
Slightly volatile
Cost Of Revenue5.7 M5.9 M36.4 M
Pretty Stable
Total Operating Expenses188.7 M230.8 M163.1 M
Slightly volatile
Non Operating Income Net Other2.1 M2.6 M1.7 M
Slightly volatile
Interest Income8.9 M8.5 M3.4 M
Slightly volatile
Tax Provision62.3 K65.5 K147 K
Very volatile
Reconciled Depreciation571 K306 K681.1 K
Slightly volatile

Karyopharm Therapeutics Cash Flow Statement

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Stock Based Compensation18.7 M14.1 M16.1 M
Slightly volatile
Begin Period Cash Flow94.1 M62.8 M81.2 M
Slightly volatile
Total Cash From Financing Activities28.5 M30 M90.2 M
Very volatile
End Period Cash Flow98.3 M60.9 M85 M
Slightly volatile
Sale Purchase Of Stock104.9 M99.9 M60.1 M
Pretty Stable
Change To Netincome22.7 M40.4 M20.7 M
Slightly volatile

Financial Ratios

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Price To Sales Ratio0.520.551999
Slightly volatile
Days Sales Outstanding53.9865.41568.1115
Pretty Stable
Stock Based Compensation To Revenue0.09140.096217.7027
Pretty Stable
Capex To Depreciation0.460.482.0247
Slightly volatile
Inventory Turnover2.271.47334.6639
Slightly volatile
Days Of Inventory On Hand218248153
Slightly volatile
Payables Turnover1.411.486110.475
Slightly volatile
Sales General And Administrative To Revenue0.870.9122.3093
Slightly volatile
Research And Ddevelopement To Revenue0.820.8688.7739
Slightly volatile
Capex To Revenue0.00110.00111.4079
Slightly volatile
Cash Per Share5.545.829459.6162
Slightly volatile
Days Payables Outstanding258246139
Slightly volatile
Income Quality0.670.38450.8321
Very volatile
Current Ratio1.061.12047.5653
Slightly volatile
Receivables Turnover6.65.57985.6108
Pretty Stable
Capex Per Share0.01910.02010.2665
Pretty Stable
Revenue Per Share8.7313.357810.1418
Slightly volatile
Interest Debt Per Share22.6126.081321.1899
Slightly volatile
Debt To Assets2.322.20770.6522
Slightly volatile
Operating Cycle272313221
Slightly volatile
Days Of Payables Outstanding258246139
Slightly volatile
Ebt Per Ebit2.272.16081.1615
Slightly volatile
Quick Ratio1.021.07667.5447
Slightly volatile
Net Income Per E B T0.81.00020.9893
Slightly volatile
Cash Ratio0.620.65765.1946
Slightly volatile
Days Of Inventory Outstanding218248153
Slightly volatile
Days Of Sales Outstanding53.9865.41568.1115
Pretty Stable
Free Cash Flow Operating Cash Flow Ratio1.121.151.0302
Slightly volatile
Fixed Asset Turnover32.9731.398810.9553
Slightly volatile
Debt Ratio2.322.20770.6522
Slightly volatile
Price Sales Ratio0.520.551999
Slightly volatile
Asset Turnover1.411.34730.3816
Slightly volatile

Karyopharm Therapeutics Valuation Data

Trends
Current ValueLast YearHistorical Average 10 Year Trend
Market Cap90 M94.7 M457.5 M
Slightly volatile

Karyopharm Fundamental Market Drivers

Karyopharm Upcoming Events

21st of February 2024
Upcoming Quarterly Report
View
2nd of May 2024
Next Financial Report
View
31st of December 2023
Next Fiscal Quarter End
View
21st of February 2024
Next Fiscal Year End
View
30th of September 2023
Last Quarter Report
View
31st of December 2022
Last Financial Announcement
View

About Karyopharm Therapeutics Financial Statements

Investors use fundamental indicators, such as Karyopharm Therapeutics' revenue or net income, to determine how well the company is positioned to perform in the future. Although Karyopharm Therapeutics' investors may analyze each financial statement separately, they are all interrelated. Understanding these patterns can help investors make the right trading decisions.
Last ReportedProjected for Next Year
Current Deferred Revenue28.8 M30.3 M
Total Revenue146.1 M153.4 M
Cost Of Revenue5.9 M5.7 M
Stock Based Compensation To Revenue 0.10  0.09 
Sales General And Administrative To Revenue 0.91  0.87 
Research And Ddevelopement To Revenue 0.86  0.82 
Revenue Per Share 13.36  8.73 
Ebit Per Revenue(0.62)(0.65)

Currently Active Assets on Macroaxis

FSLYFastly Class A
MOBMobilicom Limited American
CMGChipotle Mexican Grill
CSANCosan SA ADR
RKTRocket Companies
When determining whether Karyopharm Therapeutics offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Karyopharm Therapeutics' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Karyopharm Therapeutics Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Karyopharm Therapeutics Stock:
How To Invest In Karyopharm
Details
Is Karyopharm Stock a good investment?
Details
What is Karyopharm Therapeutics' Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Check out the analysis of Karyopharm Therapeutics Correlation against competitors.
For more detail on how to invest in Karyopharm Stock please use our How to Invest in Karyopharm Therapeutics guide.
You can also try the Portfolio Backtesting module to avoid under-diversification and over-optimization by backtesting your portfolios.
Is there potential for Biotechnology market expansion? Will Karyopharm introduce new products? Factors like these will boost the valuation of Karyopharm Therapeutics. Expected growth trajectory for Karyopharm significantly influences the price investors are willing to assign. Understanding fair value requires weighing current performance against future potential. All the valuation information about Karyopharm Therapeutics listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share
(17.93)
Revenue Per Share
13.358
Quarterly Revenue Growth
0.116
Return On Assets
(0.42)
Return On Equity
(8.91)
The market value of Karyopharm Therapeutics is measured differently than its book value, which is the value of Karyopharm that is recorded on the company's balance sheet. Investors also form their own opinion of Karyopharm Therapeutics' value that differs from its market value or its book value, called intrinsic value, which is Karyopharm Therapeutics' true underlying value. Analysts utilize numerous techniques to assess fundamental value, seeking to purchase shares when trading prices fall beneath estimated intrinsic worth. Because Karyopharm Therapeutics' market value can be influenced by many factors that don't directly affect Karyopharm Therapeutics' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Advice
Details
Earnings
Projections
Details
Understanding that Karyopharm Therapeutics' value differs from its trading price is crucial, as each reflects different aspects of the company. Evaluating whether Karyopharm Therapeutics represents a sound investment requires analyzing earnings trends, revenue growth, technical signals, industry dynamics, and expert forecasts. Meanwhile, Karyopharm Therapeutics' quoted price indicates the marketplace figure where supply meets demand through bilateral consent.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY